Back to top
more

Oculis Holding AG (OCS)

(Delayed Data from NSDQ)

$17.88 USD

17.88
96,039

+0.70 (4.08%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last?

Oculis Holding AG (OCS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Oculis Holding AG (OCS) Surges 8.2%: Is This an Indication of Further Gains?

Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -30.23% and 3.21%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates

IGM Biosciences (IGMS) delivered earnings and revenue surprises of -2,733.33% and 97.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -28.43% and 98.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Lags Revenue Estimates

Aadi Bioscience (AADI) delivered earnings and revenue surprises of 23.94% and 2.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?

Mirum Pharmaceuticals (MIRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

How Much Upside is Left in Oculis Holding AG (OCS)? Wall Street Analysts Think 152.77%

The consensus price target hints at a 152.8% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What Makes Oculis Holding AG (OCS) a Good Fit for 'Trend Investing'

Oculis Holding AG (OCS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Can Oculis Holding AG (OCS) Climb 191.31% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 191.3% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.